Valuation: MetaVia Inc.

Market Cap 8.3M 7.4M 6.86M 6.24M 11.71M 788M 11.89M 82.28M 32.31M 411M 31.15M 30.49M 1.32B P/E 2026 *
-0.5x
P/E 2027 * -0.53x
Enterprise Value 8.3M 7.4M 6.86M 6.24M 11.71M 788M 11.89M 82.28M 32.31M 411M 31.15M 30.49M 1.32B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
71.39%
Yield 2026 *
-
Yield 2027 * -
1 day-2.38%
1 week-12.77%
Current month-21.66%
1 month-28.90%
3 months-28.07%
6 months-12.14%
Current year-85.39%
1 week 1.22
Extreme 1.225
1.52
1 month 1.22
Extreme 1.225
1.7
Current year 0.97
Extreme 0.9661
9.61
1 year 0.97
Extreme 0.9661
14.85
3 years 0.97
Extreme 0.9661
74.25
5 years 0.97
Extreme 0.9661
5,618.8
10 years 0.97
Extreme 0.9661
79,200.08
Manager TitleAgeSince
Chief Executive Officer 50 2023-08-10
Director of Finance/CFO 68 2023-10-26
Chief Tech/Sci/R&D Officer - 2026-10-11
Director TitleAgeSince
Director/Board Member 55 2019-12-30
Director/Board Member 76 2019-12-30
Director/Board Member 50 2021-07-08
Date Insider Type Main position Quantity % Market Cap. Importance
10/12/26 Free

Chief Technology Officer

53,000 0.8045%
1/23/26 Free

Chief Executive Officer

32,000 1.3913%
1/23/26 Free

Chief Financial Officer

28,000 1.2174%
Change 5-day change 1-year change 3-year change Capi.($)
-2.38%-12.77%-88.50%-96.79% 8.3M
+1.52%-7.16%+51.66%+67.41% 65B
+1.52%+7.17%+10.77%+77.89% 51.2B
+0.30%+0.19%+2.53%+56.14% 51.19B
-0.38%+2.31%+29.98%+40.71% 43.93B
+0.30%+4.43%+16.99%+120.94% 41.96B
+2.35%-4.01%+236.69%+497.21% 38.14B
+2.16%+10.36%+18.92%+59.70% 33.24B
-0.90%-10.49%+37.09%+1.80% 25.2B
+1.60%+3.97%+21.34%+22.33% 22.5B
Average +0.61%-0.94%+33.75%+84.74% 37.24B
Weighted average by Cap. +0.97%+0.04%+46.03%+106.35%

Financials

2026 *2027 *
Net sales - -
Net income -19.62M -17.49M -16.22M -14.74M -27.66M -1.86B -28.1M -194M -76.36M -972M -73.6M -72.05M -3.11B -28.78M -25.67M -23.79M -21.63M -40.59M -2.73B -41.23M -285M -112M -1.43B -108M -106M -4.56B
Net Debt - -
Projected Income Statement - Annual - MetaVia Inc.
Logo MetaVia Inc.
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.
Employees
8
Date Price Change Volume
26-10-19 US$1.230 -2.38% 54,056
26-10-16 US$1.260 -8.03% 75,916
26-10-15 US$1.370 +0.74% 50,284
26-10-14 US$1.360 -4.90% 40,626
26-10-13 US$1.430 -1.38% 65,682
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - MetaVia Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.260USD
Average target price
19.33USD
Spread / Average Target
+1,434.39%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - MetaVia Inc.
  1. Stock Market
  2. Stocks
  3. MTVA Stock